Another major exhibit by the company is its world‘s first erythroid maturation agent called Luspatercept, which reduces patients' transfusion burden and is the first treatment advancement in myelodysplastic syndromes in more than a decade.

该公司的另一个主要展品是其世界上第一种名为Luspatercept的红系成熟剂，它可以减轻患者的输血负担，是十多年来骨髓增生异常综合征的首次治疗进展。

In January 2021, the Center for Drug Evaluation of China National Medical Products Administration approved EdiGene's investigational new drug application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia.

Chinese biotech company EdiGene Inc announced on Monday the Center for Drug Evaluation of the China National Medical Products Administration has approved the company's Investigational New Drug application for ET-01, a CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia, a blood disease characterized by severe anemia and a lifelong dependence on red blood cell transfusions that can lead to iron overload.

The approved trial of ET-01 is a multicenter, open-label, single arm study designed to assess safety and efficacy in transfusion dependent β-thalassemia patients.

Serious unmet medical needs remain for transfusion dependent β-thalassemia patients today.

For example, the company's Alinity™ diagnostics systems, soon to be launched in China, offer hospitals and laboratories a harmonized experience across all critical diagnostic disciplines including clinical chemistry, immunoassay, hematology, transfusion, molecular, point of care, and informatics, delivering better efficiency and flexibility to help standardize processes and reduce costs.

For example, the company's Alinity™ diagnostics systems, soon to be launched in China, offer hospitals and laboratories a harmonized experience across all critical diagnostic disciplines including clinical chemistry, immunoassay, hematology, transfusion, molecular testing, point of care and informatics, delivering better efficiency and the flexibility to help standardize processes, reduce costs and improve efficiency.

Since then, Liu said with a "blood transfusion" to the property industry, supply and demand in the market have seen noticeable improvements.